Deutsch English Français

Contact

EP2121744

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2121744

EP2121744 - TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 18.02.2011 Database last updated on 30.10.2024
Most recent event Tooltip	18.02.2011	Withdrawal of application	published on 23.03.2011 [2011/12]
Applicant(s)	For all designated states Novo Nordisk Health Care AG Andreasstrasse 15 8050 Zürich / CH
	[2009/48]
Inventor(s)	01 / HU, Sean 3840 Collins St West Sacramento, CA 95691 / US
	02 / ZHAO, Xin Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	03 / JIANHUA, Wang Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	04 / CHANG, Chihchuan Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	05 / NO̸RSKOV-LAURITSEN, Leif Strandvejen 80 DK-4733 Tapperno̸je / DK
	06 / SU, Jing No. 26 Fu Xing Road Building 26, Apartment 3-3 100851 Beijing CN-100851 / CN
	[2010/10]
Former [2010/01]	01 / HU, Sean 4314 Ashland Terrace, Unit C Davis, California CA 95618 / US
	02 / ZHAO, Xin Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	03 / JIANHUA, Wang Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	04 / CHANG, Chihchuan Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	05 / NO̸RSKOV-LAURITSEN, Leif Strandvejen 80 DK-4733 Tapperno̸je / DK
	06 / SU, Jing No. 26 Fu Xing Road Building 26, Apartment 3-3 100851 Beijing CN-100851 / CN
Former [2009/48]	01 / HU, Sean 4314 Ashland Terrace, Unit C Davis, California CA 95618 / US
	02 / ZIN, Xao Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	03 / JIANHUA, Wang Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	04 / CHANG, Chihchuan Novo Nordisk R/D Center China 1st. Floor, Tower B no. 29 Life Science Park Road Beijing CA 102208 / CN
	05 / NO̸RSKOV-LAURITSEN, Leif Strandvejen 80 DK-4733 Tapperno̸je / DK
	06 / SU, Jing No. 26 Fu Xing Road Building 26, Apartment 3-3 100851 Beijing CN-100851 / CN
Representative(s)	Nilsson, Karin Norvin Novo Nordisk A/S Corporate Patents Novo Allé 2880 Bagsværd / DK
	[N/P]
Former [2009/48]	Nilsson, Karin Norvin Novo Nordisk A/S Corporate Patents Novo Allé 2880 Bagsværd / DK
Application number, filing date	08717052.8	22.02.2008
	[2009/48]
	WO2008EP52190
Priority number, date	EP20070102886	22.02.2007 Original published format: EP 07102886
	WO2007EP58571	17.08.2007 Original published format: PCT/EP2007/058571
	[2009/48]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2008102007
	Date:	28.08.2008
	Language:	EN
	[2008/35]
	Type:	A1 Application with search report
	No.:	EP2121744
	Date:	25.11.2009
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 28.08.2008 takes the place of the publication of the European patent application.
	[2009/48]
Search report(s)	International search report - published on:	EP	28.08.2008
Classification	IPC:	C07K14/61, C12N9/10, C12N15/54	[2009/48]
	CPC:	C12N9/1044 (EP,US); C07K14/61 (KR); A61P1/00 (EP); A61P1/16 (EP); A61P11/00 (EP); A61P13/12 (EP); (+) A61P15/08 (EP); A61P15/10 (EP); A61P19/00 (EP); A61P19/02 (EP); A61P19/04 (EP); A61P19/08 (EP); A61P19/10 (EP); A61P21/00 (EP); A61P25/00 (EP); A61P25/24 (EP); A61P25/28 (EP); A61P29/00 (EP); A61P3/04 (EP); A61P31/18 (EP); A61P35/00 (EP); A61P43/00 (EP); A61P5/00 (EP); A61P5/06 (EP); A61P9/00 (EP); A61P9/10 (EP); C12N15/52 (KR); C12N9/10 (KR) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2009/48]
Title	German:	TRANSGLUTAMINASEVARIANTEN MIT VERBESSERTER SPEZIFITÄT	[2009/48]
	English:	TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY	[2009/48]
	French:	VARIANTS DE TRANSGLUTAMINASE À SPÉCIFICITÉ AMÉLIORÉE	[2009/48]
Entry into regional phase	22.09.2009	National basic fee paid
	22.09.2009	Designation fee(s) paid
	22.09.2009	Examination fee paid
Examination procedure	22.09.2009	Examination requested [2009/48]
	11.02.2011	Application withdrawn by applicant [2011/12]
Fees paid	Renewal fee
	01.03.2010	Renewal fee patent year 03
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	JPH1175876 [ ] (AJINOMOTO KK);
		[Y]EP1219713 (AJINOMOTO KK [JP]) [Y] 5,6 * page 3 - page 7; sequences 3-5,31-38 *;
		WO03074004 [ ] (CHOU SZU-YI [US]);
		US2003219857 [ ] (CHOU SZU-YI [US]);
		[A]WO2005070468 (NOVO NORDISK AS [DK], et al);
		[X]WO2006134148 (NOVO NORDISK AS [DK], et al) [X] 25 * claim - *;
		[PX]WO2007020290 (NOVO NORDISK AS [DK], et al) [PX] 1,7,9,10,12-15,18,19,21-25 * claim -; table 1; sequences 1-5 *;
		[PX]WO2007020291 (NOVO NORDISK AS [DK], et al) [PX] 1,7,9,10,12-15,18,19,21-25 * claim -; table 1; sequences 1-5 *;
		[X] - "Process for producing novel microbial transglutaminase. 120", JPO Proteins, (20010215), Database accession no. E75085, URL: EBI, XP002482286 [X] 1,4,7,9,10,12,14,15 * the whole document *
		[X] - "Transglutaminase related protein SEQ ID 5.", Geneseq, (20010713), Database accession no. AAB81161, URL: EBI, XP002482287 [X] 1,7,9-15,17 * the whole document *
		[X] - "Sequence 8 from patent US 7101695.", USPTO Proteins, (20061008), Database accession no. ABJ35274, URL: EBI, XP002482288 [X] 1,4,7,9,10,12-15 * the whole document *
		[X] - "Streptomyces cinnamoneus transglutaminase SEQ ID NO:8.", Geneseq, (20031204), Database accession no. ADB37645, URL: EBI, XP002482289 [X] 1,4,7,9,10,12-15 * the whole document *
		[XY] - "Streptomyces mobaraensis transglutaminase SEQ ID NO:6. EKGFQRAREV ASVMNRALEN AHDESAYLDN LKKELANGND ALRNEDARSP FYSALRNTPS", Geneseq, (20031204), Database accession no. ADB37643, URL: EBI, XP002482290 [X] 1,4,7,9,10,12-15 * the whole document * [Y] 5,6
		[A] - CLARK R ET AL, "Long-acting growth hormones produced by conjugation with polyethylene glycol", JOURNAL OF BIOLOGICAL CHEMISTRY, AL, (19960906), vol. 271, no. 36, ISSN 0021-9258, pages 21969 - 21977, XP002216386 DOI: http://dx.doi.org/10.1074/jbc.271.36.21969

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p